Cite
HARVARD Citation
Ongoren, S. et al. (2018). Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 23 (4), pp. 212-220. [Online].